Search Within

Michael Andrew Postow

Formats
  1. Journal Article (196)
  2. Meeting Abstract (138)
  3. Review (10)
  4. Editorial (9)
  5. Book Section (4)
  6. Guidelines (4)
  7. Research Letter (4)
  8. Miscellaneous (2)
  9. Book Whole (1)
  10. Correspondence (1)
Groups
  1. Department of Medicine (369)
  2. Melanoma Disease Management Team (369)
  3. Melanoma and Immunotherapeutics Service (369)
  4. Solid Tumor Oncology Division (369)
  5. GSK Faculty (178)
  6. Hematologic Malignancies, Division of (105)

More Groups

People
  1. Jedd Wolchok (158)
  2. Margaret Callahan (96)
  3. Katherine Panageas (66)
  4. Alexander Shoushtari (64)
  5. Paul Chapman (55)
  6. Parisa Momtaz (37)

More People

Years
  1. 2025 (23)
  2. 2024 (19)
  3. 2023 (23)
  4. 2022 (23)
  5. 2021 (27)
  6. 2020 (30)

More Years

Publications
  1. Journal of Clinical Oncology (92)
  2. Journal for ImmunoTherapy of Cancer (34)
  3. Clinical Cancer Research (16)
  4. Annals of Oncology (13)
  5. International Journal of Radiation Oncology, Biology, Physics (12)
  6. The Oncologist (12)

More Publications

Publishers
  1. American Society of Clinical Oncology (94)
  2. Biomed Central Ltd (43)
  3. Elsevier Inc. (32)
  4. Oxford University Press (32)
  5. American Association for Cancer Research (24)
  6. Wiley Blackwell (21)

More Publishers

Results (369)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety of infusing ipilimumab over 30 minutes
    Journal Article

    Momtaz, P.; Park, V.; Panageas, K. S.; Postow, M. A.; Callahan, M.; Wolchok, J. D.; Chapman, P. B.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase 1b/2 study of ribociclib (LEE011; CDK4/6 inhibitor) in combination with binimetinib (MEK162; MEK inhibitor) in patients with NRAS-mutant melanoma
    Meeting Abstract

    van Herpen, C.; Postow, M. A.; Carlino, M. S.; Kalkavan, H.; Weise, A.; Amaria, R. N.; De Vos, F.; Carvajal, R. D.; Matano, A.; Bhansali, S.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Pneumonitis with anti-PD-1/PD-L1 therapy
    Meeting Abstract

    Naidoo, J.; Cunningham, J.; Woo, K. M.; Hellmann, M. D.; Postow, M. A.; Drilon, A. E.; Chaft, J. E.; Lesokhin, A. M.; Segal, N. H.; Callahan, M. K.; more...
    European Journal of Cancer (2015)

    Fulltext@MSK | Save
  • Alternative transcription initiation leads to expression of a novel ALK isoform in cancer
    Journal Article

    Wiesner, T.; Lee, W.; Obenauf, A. C.; Ran, L.; Murali, R.; Zhang, Q.; Wong, E. W. P.; Hu, W.; Scott, S. N.; Shah, R. H.; more...
    Nature (2015)

    Fulltext@MSK | Save
  • Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center
    Journal Article

    Horvat, T. Z.; Adel, N. G.; Dang, T. O.; Momtaz, P.; Postow, M. A.; Callahan, M. K.; Carvajal, R. D.; Dickson, M. A.; D'Angelo, S. P.; Woo, K. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Elevated blood neutrophil-to-lymphocyte ratio is associated with poor survival in melanoma
    Meeting Abstract

    Davis, J.; Panageas, K.; Postow, M.; Brady, M. S.; Ariyan, C. E.; Coit, D.
    Annals of Surgical Oncology (2015)

    Fulltext@MSK | Save
  • Melanoma and non-melanoma skin cancers in hairy cell leukaemia: A Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center
    Journal Article

    Watts, J. M.; Kishtagari, A.; Hsu, M.; Lacouture, M. E.; Postow, M. A.; Park, J. H.; Stein, E. M.; Teruya-Feldstein, J.; Abdel-Wahab, O.; Devlin, S. M.; more...
    British Journal of Haematology (2015)

    Fulltext@MSK | Save
  • Safety of pembrolizumab (pem) in patients (pts) who stopped ipilimumab (ipi) due to immune-related adverse events
    Meeting Abstract

    Shoushtari, A. N.; Postow, M. A.; Horvat, T. Z.; Adel, N. G.; Dang, T.; Chapman, P. B.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma
    Meeting Abstract

    Ribas, A.; Butler, M.; Lutzky, J.; Lawrence, D. P.; Robert, C.; Miller, W.; Linette, G. P.; Ascierto, P. A.; Kuzel, T.; Algazi, A. P.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Investigation of intrapatient heterogeneity in the tumor infiltrating T cell repertoire in patients with metastatic melanoma treated with pembrolizumab
    Meeting Abstract

    Munhoz, R. R.; Merghoub, T.; Emerson, R. O.; Callahan, M. K.; Wolchok, J. D.; Postow, M. A.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save